Vanda leaps on tasimelteon Priority Review

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) gained $3.56 (44%) to $11.61 on Tuesday after FDA accepted and granted Priority Review to an NDA for tasimelteon ( VEC-162) to treat non-24-hour sleep wake dis...